Jerry L. Spivak, MD
Professor of Medicine
The Johns Hopkins University School of Medicine
Dr. Spivak received his medical degree from Cornell University Medical College. He completed an internship and residency in internal medicine at the Johns Hopkins Hospital, where he was chief medical resident and was also a clinical associate at the National Cancer Institute and a senior resident in medicine at New York Hospital. Dr. Spivak joined the faculty of the Johns Hopkins School of Medicine in 1972 and served as Director of the Hematology Division from 1980 to 1992. He is currently Professor of Medicine and Oncology and Director of the Center for the Chronic Myeloproliferative Disorders at Johns Hopkins. Dr. Spivak is a diplomate of the American Board of Internal Medicine with subspecialty certification in Hematology. He has received many awards over the course of his career, including a Research Career Development Award and a Merit Award from the National Institutes of Health. He is the author of over 200 scientific publications, holds numerous editorial appointments, and is frequently an invited speaker at national and international meetings.
Faculty Disclosure: Dr. Spivak has indicated that he is a consultant for Roche Pharmaceuticals, Novartis Pharmaceuticals & Shire Pharmaceuticals.
Cage S. Johnson, MD
Professor of Medicine
Director, Comprehensive Sickle Cell Center
Keck School of Medicine
University of Southern California
Dr. Johnson received his medical degree from Creighton University, Omaha, Nebraska and was an Rotating intern and Resident in Internal Medicine at the University of Cincinnati. He completed residency and fellowship in Hematology at the University of Southern California. He joined the faculty at USC in 1974 and is currently Professor of Medicine and of Physiology and Biophysics. In addition, he is Director of the Comprehensive Sickle Cell Center. Dr. Johnson is a diplomate of the American Board of Internal Medicine with subspecialty certification in Hematology. His research interests include the pathophysiology of hemoglobinopathies and of red blood cell enzyme defects.
Faculty Disclosure: Dr. Johnson has indicated that he is a consultant for Thios Pharmaceuticals, SuperGen Inc., Novartis Pharmaceuticals and Icagen Pharmaceuticals. He also receives grants and research support from the National Heart, Lung and Blood Institute and the National Institute of Health.
Kwaku Ohene-Frempong, MD
Professor of Pediatrics
Director, Sickle Cell Program and Comprehensive Sickle Cell Center
The Children’s Hospital of Philadelphia
Dr. Ohene-Frempong is a full-time member of the faculty of the University of Pennsylvania School of Medicine where he is Professor of Pediatrics. He is board certified in Pediatrics and Pediatric Hematology-Oncology and is an Attending Hematologist and Director of the Sickle Cell Center at The Children’s Hospital of Philadelphia. He is also Program Director of the NIH-funded Comprehensive Sickle Cell Center at CHOP. He is the current Chairman of the Board of Directors of the Sickle Cell Disease Association of America. Dr. Ohene-Frempong’s undergraduate education was at Yale University and was followed by medical education at Yale School of Medicine. His Pediatric Residency was at New York Hospital–Cornell Medical Center. His fellowship in Pediatric Hematology-Oncology was done under Elias Schwartz, MD, at The Children's Hospital of Philadelphia.
Faculty Disclosure: No relationship with commercial supporters.